Sign In
Buy IPGP
IPG Photonics Earnings Calls
| Release date | Nov 04, 2025 |
| EPS estimate | $0.160 |
| EPS actual | $0.350 |
| EPS Surprise | 118.75% |
| Revenue estimate | 247.675M |
| Revenue actual | 250.792M |
| Revenue Surprise | 1.26% |
| Release date | Aug 05, 2025 |
| EPS estimate | $0.100 |
| EPS actual | $0.300 |
| EPS Surprise | 200.00% |
| Revenue estimate | 239.131M |
| Revenue actual | 250.721M |
| Revenue Surprise | 4.85% |
| Release date | May 06, 2025 |
| EPS estimate | $0.210 |
| EPS actual | $0.310 |
| EPS Surprise | 47.62% |
| Revenue estimate | 239.884M |
| Revenue actual | 227.793M |
| Revenue Surprise | -5.04% |
| Release date | Feb 11, 2025 |
| EPS estimate | $0.230 |
| EPS actual | $0.180 |
| EPS Surprise | -21.74% |
| Revenue estimate | 233.229M |
| Revenue actual | 234.337M |
| Revenue Surprise | 0.475% |
Last 4 Quarters for IPG Photonics
Below you can see how IPGP performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 11, 2025 |
| Price on release | $63.72 |
| EPS estimate | $0.230 |
| EPS actual | $0.180 |
| EPS surprise | -21.74% |
| Date | Price |
|---|---|
| Feb 05, 2025 | $71.72 |
| Feb 06, 2025 | $70.82 |
| Feb 07, 2025 | $68.91 |
| Feb 10, 2025 | $67.40 |
| Feb 11, 2025 | $63.72 |
| Feb 12, 2025 | $62.97 |
| Feb 13, 2025 | $62.88 |
| Feb 14, 2025 | $63.53 |
| Feb 18, 2025 | $63.98 |
| 4 days before | -11.15% |
| 4 days after | 0.408% |
| On release day | -1.18% |
| Change in period | -10.79% |
| Release date | May 06, 2025 |
| Price on release | $54.91 |
| EPS estimate | $0.210 |
| EPS actual | $0.310 |
| EPS surprise | 47.62% |
| Date | Price |
|---|---|
| Apr 30, 2025 | $59.89 |
| May 01, 2025 | $61.80 |
| May 02, 2025 | $63.80 |
| May 05, 2025 | $63.13 |
| May 06, 2025 | $54.91 |
| May 07, 2025 | $57.88 |
| May 08, 2025 | $58.73 |
| May 09, 2025 | $60.15 |
| May 12, 2025 | $64.81 |
| 4 days before | -8.32% |
| 4 days after | 18.03% |
| On release day | 5.41% |
| Change in period | 8.22% |
| Release date | Aug 05, 2025 |
| Price on release | $74.63 |
| EPS estimate | $0.100 |
| EPS actual | $0.300 |
| EPS surprise | 200.00% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $77.04 |
| Jul 31, 2025 | $74.89 |
| Aug 01, 2025 | $75.22 |
| Aug 04, 2025 | $77.46 |
| Aug 05, 2025 | $74.63 |
| Aug 06, 2025 | $72.14 |
| Aug 07, 2025 | $74.73 |
| Aug 08, 2025 | $75.26 |
| Aug 11, 2025 | $75.46 |
| 4 days before | -3.13% |
| 4 days after | 1.11% |
| On release day | -3.34% |
| Change in period | -2.05% |
| Release date | Nov 04, 2025 |
| Price on release | $84.00 |
| EPS estimate | $0.160 |
| EPS actual | $0.350 |
| EPS surprise | 118.75% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $86.37 |
| Oct 30, 2025 | $84.11 |
| Oct 31, 2025 | $85.12 |
| Nov 03, 2025 | $85.90 |
| Nov 04, 2025 | $84.00 |
| Nov 05, 2025 | $88.95 |
| Nov 06, 2025 | $89.75 |
| Nov 07, 2025 | $87.94 |
| Nov 10, 2025 | $86.57 |
| 4 days before | -2.74% |
| 4 days after | 3.06% |
| On release day | 5.89% |
| Change in period | 0.232% |
IPG Photonics Earnings Call Transcript Summary of Q3 2025
IPG Photonics reported Q3 2025 revenue of $251M (flat sequential, +8% YoY; +11% excluding divestitures), with results at the top end of expectations. Key industrial drivers were stronger welding demand tied to e-mobility and stationary battery storage, steady cutting, robust additive manufacturing, and continued growth in laser cleaning following the cleanLASER acquisition. Emerging growth products accounted for 52% of sales. The company received FDA clearance for its next-generation thulium urology system and expects shipments to begin in Q4, marking a key medical growth milestone with recurring consumable opportunity. IPG showcased CROSSBOW, a scalable directed-energy solution for small drones, and opened a defense customer/production center in Huntsville, AL; commercialization discussions are underway with multiple customers. Financials: adjusted gross margin ~39.8%, adjusted EBITDA $37M, adjusted EPS $0.35, cash + short-term investments ~$870M, no debt. Tariffs negatively impacted margins (~140 bps), and management is pursuing mitigation strategies. Q4 guidance: revenue $230M–$260M, adjusted gross margin 36%–39%, OpEx $90M–$92M, adj. EPS $0.05–$0.35. Management emphasized a multi-year strategic transformation to a team-led operating model, continued investments in medical, micromachining and defense, and cautious optimism on demand as PMIs improve. Capital allocation included $16M of share repurchases and ~$21M of CapEx in the quarter.
